2.69 0.02 (0.75%) | 05-03 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 3.58 | 1-year : | 4.18 |
Resists | First : | 3.06 | Second : | 3.58 |
Pivot price | 2.5 | |||
Supports | First : | 2.6 | Second : | 2.3 |
MAs | MA(5) : | 2.65 | MA(20) : | 2.53 |
MA(100) : | 2.8 | MA(250) : | 2.95 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 59.3 | D(3) : | 54.6 |
RSI | RSI(14): 54.4 | |||
52-week | High : | 4.65 | Low : | 2.27 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NAUT ] has closed below upper band by 12.4%. Bollinger Bands are 2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 2.82 - 2.84 | 2.84 - 2.85 |
Low: | 2.61 - 2.62 | 2.62 - 2.64 |
Close: | 2.67 - 2.69 | 2.69 - 2.71 |
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Fri, 03 May 2024
Nautilus Biotechnology (NAUT) Upgraded to Buy: Here's What You Should Know - Zacks Investment Research
Wed, 01 May 2024
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2024 Earnings Call Transcript - Insider Monkey
Tue, 30 Apr 2024
Nautilus Biotechnology, Inc. (NAUT) Q1 2024 Earnings Call Transcript - Seeking Alpha
Tue, 30 Apr 2024
Nautilus Biotechnology Reports First Quarter 2024 Financial Results - GlobeNewswire
Sun, 28 Apr 2024
Nautilus Biotechnology (NAUT) Scheduled to Post Quarterly Earnings on Tuesday - Defense World
Thu, 11 Apr 2024
Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024 - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 125 (M) |
Shares Float | 41 (M) |
Held by Insiders | 33.6 (%) |
Held by Institutions | 49.7 (%) |
Shares Short | 1,200 (K) |
Shares Short P.Month | 1,310 (K) |
EPS | -0.51 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 2.11 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -14.6 % |
Return on Equity (ttm) | -22 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -0.6 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -52 (M) |
Levered Free Cash Flow | -32 (M) |
PE Ratio | -5.28 |
PEG Ratio | 0 |
Price to Book value | 1.26 |
Price to Sales | 0 |
Price to Cash Flow | -6.51 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |